IASO Bio Appoints Dr. Biao Zheng as Chief Scientific Officer and Dr. Wen Wang as Chief Medical Officer
IASO Bio, a clinical-stage company focused on developing and commercializing novel cellular immunotherapy to treat cancer, is pleasant to announce the appointment of Dr. Biao Zheng as Chief Scientific Officer (CSO), and the appointment of Dr. Wen Wang as Chief Medical Officer (CMO).
Dr. Biao Zheng is a Senior Immunologist with over 25 years of extensive experience in scientific research and industry. He had made significant contributions to the immunology field.Dr. Zheng holds a Ph.D. in Clinical Medicine from Zhejiang University School of Medicine and a Ph.D. in Immunology from University of London. Prior to joining IASO BIO, he taught at University of Maryland School of Medicine and Duck University Medical Center, he was Tenured Professor of the Department of Pathology and Immunology at Baylor College of Medicine. Dr. Zheng has led the early research and development of GSK’s immune diseases and served as Vice President of Immunotherapy at Johnson & Johnson.
After joining IASO BIO, Dr. Zheng will be responsible for developing the company's product strategic plans and accelerating R&D progress of pipeline products.
“IASO BIO is showing leapfrog growth with rapid development speed and vigorous passion. The company has entered into the commercialization preparation stage and become the first echelon of domestic cellular immunotherapy R&D and industrialization.” Commented Dr. Zheng. “At this exciting moment, I will work with the company to create a new R&D strategy, establish and improve the independent, industry-leading technology platform, and create innovative product pipelines through independent research and cooperation. Bring life miracles and hope to patients in tumors and other unmet need disease.”
Dr. Wen Wang is dedicated in cellular therapies industry for over 10 years and also has 5 years clinical experience as a surgical resident and attending physician. Dr. Wang holds a Bachelor of Clinical Medicine from Anhui Medical University, a Master of Human Anatomy from Tongji University, a M.D. from Tongji University/Würzburg University, and a Ph.D. in Molecular Biology from University of Aberdeen. Prior to joining IASO BIO, he served in CBMG, JW Therapeutics, and Simcere Pharmaceutical Group. As the key member of the project, Dr. Wang successfully applied for China's first CD19 CAR-T clinical trial and has published more than 20 SCI papers related to cell therapy in journals such as Clin Cancer Res, Blood as co-first author and corresponding authors. Dr. Wang has extensive experience in team management and clinical research strategies. Since March 2020, he served as CMO of IASO BIO and took fully responsible for clinical research.
“I am excited to join IASO BIO and it is an innovative and hardworking team. I hope to make progress with every one of the team to bring the unique products to the market together.” Dr. Wang said.
“Dr. Zheng has made significant academic contributions which combine scientific research and industrial theory. We are confident that Dr. Zheng will lead the company in scientific research innovation. Dr. Wang has rich clinical research experience in cell drugs and will be a key role in strengthening our R&D capabilities and accelerating clinical research. The strong addition to the leadership team will strengthen our R&D capacities and increase the company’s pace of research in cellular immunotherapy. ” Co-Founder Jinhua Zhang said, “We will continue to introduce more professional talents to the company in the future, striving to become an influential innovative pharmaceutical company in the industry and bring patients more hopes.”
About IASO BIO
Founded in March 2017, IASO Bio is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a 2,300㎡ GMP production platform, a 4,600㎡ R&D platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 330 staff.
The company specializes in the development of innovative hematological tumor cell drugs and antibody drugs, and expands to solid tumors and autoimmune diseases. Its own fully human antibody platform provides high-quality antibody sequences for the development of cell drugs and antibody drugs. The company’s autologous CAR-T product, CT103A, targeting BCMA, has obtained a Phase Ib/II Licence from the National Center for Drug Evaluation (CDE) and completed the Phase I clinical trial. Currently the company has more than ten pipeline products initiated by researchers which are undergoing clinical trials.
